Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroug... ( GAITHERSBURG Md. Dec. 18 /- Pana...)

HOME >> BIOLOGY >> TECHNOLOGY

Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroughs of 2007

Date:12/18/2007

GAITHERSBURG, Md., Dec. 18 /PRNewswire/ -- Panacea Pharmaceuticals' lung cancer diagnostic test, LC Detect(SM), has been named one of Time Magazine's Ten Biggest Medical Breakthroughs of 2007 (Due to length of URL, please cut and paste into browser: http://www.time.com/time/specials/2007/top10/article/0,30583,1686204_1686252_1690390, 00.html) LC Detect(SM) is a simple blood test to facilitate the identification of lung cancer, even among individuals with early-stage disease. Panacea Laboratories, a division of Panacea Pharmaceuticals, is certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA). The blood sample can be ordered by any physician and sent to Panacea for testing; sample and shipping requirements are available at http://www.panacea-labs.com.

Lung cancer accounts for the highest number of cancer deaths worldwide, in both men and women. An estimated 213,380 new cases of cancer involving the lung or bronchus are expected in the U.S. in 2007, accounting for about 15 percent of total cancer diagnoses. An estimated 160,390 deaths, accounting for about 29 percent of all cancer deaths, are expected to occur in 2007. Since 1987, more women have died each year from lung cancer than from breast cancer. Lung cancer was the third most common cancer for men and the fifth most common cancer for women in Japan in 2000. The five-year survival rate for lung cancer is only 15 percent. Survival rates for individuals in whom lung cancer is detected at an early stage while it remains localized are as high as 50 percent. Current screening and detection methods rely on imaging modalities, primarily chest x-ray and CT scanning. However, chest x-ray is not sufficiently sensitive and CT scanning is expensive with only a moderate improvement in sensitivity. Newer tests, suc
'/>"/>

SOURCE Panacea Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

1

GOOD

Page: 1 2 3 4
Related biology technology :

1. Panacea Pharmaceuticals Announces the Availability of BC Detect(SM), a Serum- Based Diagnostic Test for Breast Cancer
2. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
3. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
4. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
5. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
6. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
7. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
8. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
9. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
10. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
11. Drug Royalty Corporation (DRC) Announces Acquisition Regarding PEG-INTRON(R) From Enzon Pharmaceuticals, Inc. (ENZN)

Post Your Comments:

Panacea Pharmaceuticals' Lung Cancer Diagnostic Test, LC Detect(SM), Named One of Time Magazine's Ten Biggest Medical Breakthroug...( GAITHERSBURG Md. Dec. 18 /- Pana...)